Viroclinics Biosciences B.V. Relocation Will Broaden Scope and Accelerate Turnaround
ROTTERDAM, The Netherlands, October 4, 2012 /PRNewswire/ –
Viroclinics Biosciences B.V. has relocated to the Rotterdam Science Tower, a new
high-tech science facility that’s about to become a hotspot for international life
sciences, medical innovations and spin-offs from Erasmus MC and Erasmus University
Rotterdam. This location will form the core of a powerful cluster of biomedical
businesses, bringing a vast range of medical knowledge and business activity together
within a small area.
Viroclinics Biosciences B.V. occupies 3000m2 of office and lab space within the
building, including fully operational BSL2 and BSL3 virology laboratories for performing
state-of-the-art clinical and preclinical services.
The Rotterdam Science Tower opens on 4th October.
Enhanced collaboration improves knowledge and speed
This relocation brings Viroclinics Biosciences into close proximity to its research
and development partner, Erasmus MC. The move will further enhance the intense
collaboration between the two, increasing the opportunities for customers to benefit from
the combined scientific knowledge and skills maintained in both laboratories.
According to Hans Bunschoten, COO of Viroclinics Biosciences B.V., “The new facilities
will allow us to further streamline our logistic processes, increasing the quality and
improving the turnaround time of our services. In this setting we can offer the full range
of virology services for new drug development programs and post-marketing surveillance of
existing drugs and vaccines, ranging from traditional virology assays to the latest deep
sequencing protocols for a very broad range of viruses”.
Expanding the scope
Prof. Ab Osterhaus, Head of the Erasmus MC Viroscience Lab and CSO of Viroclinics
Biosciences B.V believes this relocation will also help Viroclinics expand its unique
position at the forefront of state-of-the-art clinical and preclinical services,
broadening both its customer base and portfolio of virus assays.
According to Bob van Gemen, CEO of Viroclinics, “With the move to the new facilities
in the Rotterdam Science Tower, we can continue to grow our organization and fulfil the
expanding need for services to support the clinical and preclinical studies of new drugs
A consultative approach to drug and vaccine development
Viroclinics Biosciences is a contract research organization providing an array of
best-in-class services to the biopharmaceutical industry including diagnostic testing,
preclinical services and general consultancy to accelerate the development of vaccines,
anti-virals and in-vitro diagnostics.
A frontrunner in improving human and animal health, the company adopts a uniquely
consultative approach, nurturing deep client relationships to fully understand needs and
provide optimally customised research programs.
All projects are performed in compliance with established international guidelines
under an ISO 15189 accredited quality system.
SOURCE Viroclinics Biosciences B.V.